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Objective: Open surgical repair (OSR) for chronic type B aortic dissection (CTBAD) has an associated morbidity and
mortality. The role of thoracic endovascular aortic repair (TEVAR) in CTBAD has not been determined. We analyzed our
contemporary experience of CTBAD undergoing OSR to identify high-risk patients who may be considered for TEVAR.
Methods: From 1999 to 2010, 221 patients had repair of descending thoracic and thoracoabdominal aortic aneurysms,
including 86 patients with CTBADs. We analyzed this cohort for mortality, complications, length of stay, and
reinterventions.
Results: OSR was performed in 25 (29%) and 61 (71%) patients for descending thoracic and thoracoabdominal CTBAD,
respectively. Median age was 57.0 years (interquartile range [IQR], 52.0-64.2 years), and median diameter was 6.0 cm
(IQR, 5.0-6.9 cm). Fifty-nine patients (69%) were male. Eight (9%) were treated for rupture. Follow-up duration was
4.6 years (IQR, 2.8-6.9 years). Hospital mortality occurred in ﬁve patients (5.8%). Cardiopulmonary bypass was used in
83 patients (97%) and deep hypothermic arrest in 36 (42%). Two patients (2.3%) each developed paraplegia, stroke, and
renal failure requiring permanent hemodialysis in the postoperative period. Length of stay was 13.5 days (IQR, 10.0-
21.0 days). Univariate predictors of hospital death included redo operations and prolonged pump time (P < .05). Six
patients (7%) had aortic-related reoperations at 4.3 years (IQR, 2.7-5.2 years): one for an ascending aortic aneurysm and
ﬁve for descending aortic aneurysms. Overall survival at 1, 5, and 7 years was 92%, 83%, and 70%, respectively, and
freedom from reoperation was 99%, 90%, and 86%, respectively.
Conclusions: OSR of CTBAD is a durable option with low mortality. Patients requiring redo operations or anticipated
prolonged pump time need further evaluation to determine whether conventional OSR or TEVAR, if feasible, is the
optimal treatment option. (J Vasc Surg 2014;59:1217-23.)Traditionally, patients with aneurysms resulting from
chronic type B aortic dissections (CTBADs) underwent
open surgical repair (OSR). Data from historical series of
the 1980s showed that these operations were associated
with a high mortality of up to 27%.1 This provided an
incentive to introduce endovascular surgery as a means to
repair this pathology. In 1999, Dake et al2 and Nienaber
et al3 ﬁrst introduced the concept of endovascular stent
graft closure of the proximal entry tear as a novel treatment
option for acute aortic dissection. Several centers have since
published outcomes on the safety and short-term efﬁcacy
of this technique for CTBAD.4,5
In recent years, there has been a preferential swing in
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://dx.doi.org/10.1016/j.jvs.2013.11.002for CTBAD. This has occurred despite concerns that the
presence of multiple fenestrations and the established
nature of the false lumen (FL) decrease the likelihood of
complete FL thrombosis and cure of the dissection.6 The
long-term outcomes of TEVAR for CTBAD are not
known.7,8
There remains a paucity of data on OSR of CTBAD us-
ing present-day techniques. The few published series of
OSRs during the last 10 years have reported a trend toward
improvements in morbidity and mortality. Centers that
perform a high volume of aortic surgery report mortality
rates ranging between 2.2% and 9.6%.9-11
The role of TEVAR in CTBAD has not been deter-
mined. The purpose of this study was to evaluate our
contemporary experience of CTBAD undergoing OSR to
identify high-risk patients that may be considered for
TEVAR and to provide contemporary data to serve as a
benchmark against which TEVAR can be compared.
METHODS
This is a retrospective examination of patients who had
OSR of CTBAD from July 1999 to August 2010. The data
were prospectively captured in the Clinical Registry for
Aortic Surgery, which has approval from the Institutional
Review Board (No. M11-061-B.)
Surgical technique. The operation in most patients
was completed with the aid of distal aortic perfusion, mild
permissive hypothermia (32C-34C), and cerebrospinal1217
Table I. Patient demographics
Variables
No. (%) or median
(IQR) (N ¼ 86)
Males 59 (69)
Age, years 57.0 (52.0-64.2)
Aortic diameter, cm 6.0 (5.3-6.9)
Chronic obstructive pulmonary disease 22 (25)
Hemodialysis preoperatively 5 (6)
Chronic renal failure (creatinine
>2.5 mg/dL)
11 (13)
Baseline creatinine, mg/dLa 1.2 (0.9-1.5)
Hypertension 81 (94)
Previous stroke/paraplegia 11 (13)
Marfan syndrome 7 (8)
Previous cardioaortic surgery 29 (34)
Ascending aorta 10 (12)
þ Hemiarch 7 (8)
þ Total arch 12 (14)
Location of CTBAD








CTBAD, Chronic type B aortic dissection; IQR, interquartile range.
aMilligram per deciliter.
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1218 Conway et al May 2014ﬂuid (CSF) drainage. Deep hypothermic circulatory arrest
(DHCA) was used in patients where proximal aortic
clamping was not possible secondary to encroachment of
the aneurysm on the left subclavian artery. DHCA is a neu-
roprotective technique that uses circulatory arrest at pro-
found hypothermia (18C) to enable operations in the
aortic arch or proximal descending thoracic aorta to be per-
formed in a bloodless ﬁeld. A clamp-and-sew technique
was used infrequently in patients with isolated descending
thoracic aneurysms or type IV thoracoabdominal aortic
aneurysms. In patients with Marfan syndrome, we avoided
the island technique and used prefabricated grafts with
individual bypasses to the intercostal, renal, and visceral
arteries when required. Those who presented with a con-
tained rupture who were hemodynamically stable were also
included in this study because the rupture did not affect the
mode of treatment.
Somatosensory-evoked potentials (SSEPs) were insti-
tuted into our practice in 2005 and motor-evoked poten-
tials in 2010. Upper and lower extremity SSEP signals, as
well as eight channels of electroencephalogram signals,
were recorded according to established standards.12,13
Analysis was performed on SSEP data only because there
were insufﬁcient numbers of patients with motor-evoked
potentials to draw any meaningful conclusions.
The proximal intercostal arteries down to the T6 level
were routinely sacriﬁced immediately after the aneurysm
was opened. The T7 to L1 intercostal arteries were left
open. In patients who did not undergo SSEP monitoring,
all patent intercostal arteries from T7 to L1 were reim-
planted using the island technique after the construction
of the proximal anastomosis. In patients who were moni-
tored with SSEP, the decision to perform intercostal artery
reimplantation (IAR) was made only after discontinuation
of the distal aortic perfusion, removal of the proximal
clamp, establishment of pulsatile ﬂow, and optimization
of hemoglobin, oxygen saturation, and CSF pressure. If
the SSEP signals did not recover, IAR was performed
with a separate 10-mm graft.
CSF drainage was performed routinely in all patients if
feasible. The CSF pressure was kept #10 mm Hg during
surgery by draining a maximum of 15 mL of CSF per
hour. As has been reported by others, the CSF pressure
was kept <10 mm Hg by draining a maximum 15 mL of
CSF every hour for 48 hours postoperatively.9,13 During
this time, spinal cord perfusion pressure is at its lowest
and most vulnerable to ischemic insults. Collateral ﬂow in-
creases at 48 to 72 hours, and the risk of ischemia reduces.
We avoided excessive CSF drainage, particularly in patients
who had intact SSEPs at the end of surgery or who awoke
neurologically intact, to avoid complications from excessive
CSF drainage. Three postoperative doses of methylprednis-
olone were given in cases of DHCA.
Follow-up. Postoperative events were compiled and
analyzed according to Guidelines for Reporting Morbidity
and Mortality after Cardiac Valvular Operations.
Data processing and statistical analysis. Patients
were randomly assigned individual identiﬁcation numbersin accordance with Health Insurance Portability and
Accountability Act regulations. Patient information was
then exported into Excel software (Microsoft Corp, Red-
mond, Wash) for blinded analysis. All analyses were per-
formed with SPSS 16.0.2 software (IBM SPSS Inc,
Chicago, Ill). Demographic and intraoperative continuous
variables were compared using an unpaired t-test or the
Mann-Whitney U test, and categoric variables and risk
factor associations were assessed using the Fisher exact test.
Values are expressed as median (interquartile range [IQR])
or as a percentage. Long-term survival probabilities were
estimated from a Kaplan-Meier life table. A P value of <.05
was considered to indicate statistical signiﬁcance.RESULTS
From July 1999 to August 2010, 221 patients under-
went repair of descending thoracic and thoracoabdominal
aortic aneurysms, including 86 patients with CTBADs.
Median duration of follow-up was 4.6-years (IQR, 2.8-
6.9 years). Table I summarizes patient demographics, clin-
ical characteristics, and location of the CTBAD.
Eight patients (9%) presented with contained rupture,
all of which were hemodynamically stable. SSEPs were
recorded in 21 patients (24%). A clamp-and-sew technique
was performed in six patients (7%).DHCAwas used in 36pa-
tients (42%), with a median arrest time of 29.0 minutes
(IQR, 24.0-33.8 minutes). Cardiopulmonary bypass time
was 77.0 minutes (IQR, 40.0-198.0 minutes), and aortic
cross-clamp time was 47.0 minutes (IQR, 34.5-60.0
Table II. Summary of postoperative complications
Complication




Spinal cord injury (total) 2 (2.3)
Spinal cord injury (late) 1 (1.1)
Respiratory
Reintubation 19 (22)
Ventilator support >48 hours 34 (40)
Renal failure requiring permanent
hemodialysis
2 (2.3)
ICU stay, days 5.5 (3.0-13.0)
Hospital stay, days 13.5 (10.0-21.0)
ICU, Intensive care unit; IQR, interquartile range.
Table III. Causes of in-hospital mortality
Patient Cause of death
1 Left lung hemorrhage, inability to oxygenate
2 Left lung hemorrhage, inability to oxygenate
3 Right ventricular failure
4 Postoperative ventricular ﬁbrillation cardiac arrest
5 Respiratory failure, necrosing pancreatitis








Female sex 0.373 0.027
Asymptomatic presentation 1 0.702
Pain at presentation 1 0.769
Rupture at presentation 0.094 1
Marfan syndrome 0.409 0.157
Hypertension 1 0.593
COPD 0.172 0.588
Diabetes mellitus 1 0.451
CVA 0.168 0.437
Baseline creatinine >2.5 mg/dL 0.572 0.437
CRF requiring hemodialysis 1 0.326
Site-speciﬁc redo 0.024 0.752
Previous ascending aneurysm repair 0.416 0.788
Previous arch repair 0.601 0.216
Previous AAA repair 0.197 0.059
Previous operation 0.173 0.786
Changes on SSEP monitoring 1 1
IAR 0.086 0.405
Cardiopulmonary bypass used 1 1
DHCA used 0.078 0.188
CSF drainage 0.589 0.478
Paraplegia 1 1
Postoperative CVA 0.135 1
Reoperation for bleeding 1 1
Tracheostomy 0.094 0.356
Reintubation 0.61 0.13
Ventilator support >48 hours 1 0.19
Early complication . 0.06
Reintervention . 0.059
Crawford extent
Pearson c2 0.538 0.581
Likelihood ratio 0.494 0.508
Age 0.196 0.564
Size of descending aorta 0.068 0.313
Aortic clamp time 0.98 0.996
Total pump time 0.015 0.657
ICU days 0.532 0.003
Hospital days 0.344 0.008
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary
disease; CRF, chronic renal failure; CSF, cerebrospinal ﬂuid; CVA, cere-
brovascular accident; DHCA, deep hypothermic circulatory arrest; IAR,
intercostal artery implantation; ICU, intensive care unit; SSEP,
somatosensory-evoked potential.
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(53%) and left atrial-femoral bypass in 37 (43%). IAR was
performed in 45 patients (55%). When IAR was used, a me-
dian of ﬁve pairs (IQR, 3-6 pairs) of artery segments were
reimplanted. CSF drainage was attempted in all patients
but could not be performed in 11 patients (14%) due to tech-
nical difﬁculties.
Postoperative complications are summarized in
Table II. Strokes were conﬁrmed by computed tomogra-
phy or magnetic resonance imaging. Hospital mortality,
deﬁned as death in the hospital during recovery or
#30 days after operation, occurred in ﬁve patients
(5.8%). Causes of hospital mortality are summarized in
Table III. In the case of early paraplegia, CSF drainage
was performed perioperatively. No ischemic insult was
detected by SSEP monitoring. IAR was not performed in
this case.
Univariate analysis of in-hospital and long-term mortal-
ity is summarized in Table IV. The univariate predictors of
in-hospital mortality included increasing pump time and a
site-speciﬁc redo operation (P < .05). Patients who pre-
sented with contained rupture showed a trend toward sig-
niﬁcance as a predictor of in-hospital mortality. Of the 81
operative survivors, 20 (24.7%) died during a median
follow-up of 3.6 years (IQR, 2.4-6.4 years). Univariate pre-
dictors of long-term mortality included female sex and
intensive care unit (ICU) length of stay (P < .05), whereas
the need for reintervention, early complications, and previ-
ous abdominal aortic aneurysm repair showed a trend to-
ward signiﬁcance as a predictor of long-term mortality.
Overall survival at 1, 5, and 7, years was 92%, 83%, and
70%, respectively (Fig 1).
As has been performed in other studies to better eval-
uate the true overall effect of the surgical approach, a com-
posite of 1-year mortality (including hospital deaths) and
the three major complications of stroke, permanent hemo-
dialysis, and paraplegia, deﬁned as adverse outcome, was
calculated.9 An adverse outcome occurred in 12 patients
(14%). A comparison was made between patients who
presented with a contained rupture and those with nonrup-
ture, looking at 1-year mortality and the same three majorcomplications. No signiﬁcant difference was observed be-
tween these two groups.
In the 79 patients still alive at 1 year, long-term survival
was calculated at 97%, 85%, and 77% at 1, 5, and 7 years,
Fig 1. Kaplan-Meier survival curve shows survival after open surgical repair (OSR) for chronic type B aortic dissection
(CTBAD).
Table V. Indications for surgery in those patients
undergoing aortic-related reoperation after open surgical
repair (OSR) for chronic type B aortic dissection
(CTBAD)
Patient Indication for reoperation
1 Aneurysmal degeneration of aorta distal to graft,
involving the celiac, superior mesenteric, and both
renal arteries
2 Aneurysmal degeneration of aorta distal to graft
involving the superior mesenteric and both renal
arteries
3 Pseudoaneurysm at the proximal suture line
4 Aneurysmal degeneration of aorta distal to graft,
involving the celiac, superior mesenteric, and both
renal arteries
5 Aneurysmal degeneration of infrarenal abdominal aorta
and bilateral common iliac artery aneurysm
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period, ﬁve patients (5.8%) underwent downstream
aortic-related surgery due to expansion of a pre-existing
aortic dissection at a median of 4.3 years (IQR, 2.7-
5.2 year). The indications for reoperation are summarized
in Table V. Freedom from reoperation was 99%, 90%,
and 86% at 1, 5, and 7 years, respectively (Fig 2).
DISCUSSION
The management of patients with acute aortic dissec-
tions has improved during recent years. As such, the num-
ber of patients with CTBADs and secondary aneurysmal
dilatation has increased.14 Repair of CTBAD is recommen-
ded in patients with an aortic diameter >5.5 cm. In those
with aortic diameters of <5.5 cm, repair is indicated for
rapid aortic growth (>1 cm/y), female patients, and all
symptomatic aneurysms.6,15,16 This explains the observa-
tion in our cohort of repair in patients with diameters
of <5.5 cm. Open surgery has traditionally been used to
treat this pathology. Although this procedure has histori-
cally been associated with a high mortality, more recent
outcomes suggest a mortality in the range of 8% to
9.6%.1,9,10,17
The enthusiasm of TEVAR for CTABD has grown
because it offers a less invasive alternative to OSR and a
decreased 30-day morbidity and mortality.18 Less encour-
aging midterm results after TEVAR have been published,
with some reporting failure of the procedure in 37% of pa-
tients #36 months due to endoleak, development of an
aneurysm of the distal aorta, or continued FL perfusion
with aneurysmal dilatation.19 Thus, the current preference
for endovascular therapy in CTBAD has been questioned.The hospital mortality in our series was 5.8%, congruent
with other recent studies.9,10 An interdisciplinary expert
consensus on the management of type B aortic dissection
found only three contemporary data series on outcomes of
OSR for CTBAD, with an early mortality rate of 8.0%
(95% conﬁdence interval, 4.5%-13.9%).9,16,20 Improve-
ments in preoperative optimization, perioperative critical
care management, perfusion strategies, and techniques to
prevent paraplegia and stroke are likely to account for a
lower mortality compared with historical data sets.
Early outcomes after TEVAR for CTBAD have been
analyzed in two large meta-analysis and quote a 30-day
mortality of 3.2%.8,18 Within this sample, 30-day mortality
Fig 2. Kaplan-Meier curve shows freedom from reintervention after repair of chronic type B aortic dissection
(CTBAD).
Table VI. Overall survival after open surgical repair (OSR) of chronic type B aortic dissection (CTBAD)
Study (ﬁrst author) Study period Patients, No.
Survival, %
1 year 2 years 3 years 5 years 7 years 10 years
This study Jul 1999-Aug 2010 86 92 . . 83 70 .
Corvera11 Jan 1995-Dec 2009 93 93 . 90 79 . 61
Pujara10 Jan 2000-Dec 2007 169 76 69 . 55 . .
Zoli9 Jan 1994-Apr 2007 104 78 . . 68 . 59
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greater expertise that performed a higher volume of
TEVAR had improved in-hospital outcomes.18
Midterm and long-term survival reported in published
registries for OSR of CTBAD are summarized in Table VI.
In those patients still alive at 1 year, our long-term survival
of 99%, 90%, and 86% at 1, 5, and 7 years, respectively, is
similar to the 98%, 83%, 76% at 1, 5, and 10 years, respec-
tively, that was published by Zoli et al.9 Using New York
State life tables, this group compared death rates with a
population matched for age and sex and found no signiﬁ-
cant difference between 1-year survivors and a New York
State-comparable population. Restoration to normal
long-term survival in those patients alive at 1 year after sur-
gery reafﬁrms the ability of surgery to reverse the natural
history of CTBAD.
A meta-analysis of endovascular repair for CTBAD
performed by Eggebrecht et al18 involving 609 patients
demonstrated survival rates of 92.7% at 1 year and 91.1%
at 2 years. Thrumurthy et al8 revealed a midterm mortalityof 9.2% (46 of 499) with a median follow-up of 24 months
in a recently published meta-analysis of TEVAR for
CTBAD. Within those studies reviewed, survival ranged
from 100% at 5 years to 59.1% at 4 years.25,26 Case selec-
tion heterogeneity, unreported surgical turndown rates, a
small sample size, and the immature nature of existing da-
tabases were given as explanations for the wide range in
survival rates.8 Long-term survival data after TEVAR are
not yet available.
Median ICU stay in our cohort was 5.5 days, and hos-
pital stay was 13.5 days. Others report an ICU stay of 4.0
to 6.2 days and a hospital stay of 10.5 to 18.3 days. The
average ICU and hospital stay after TEVAR has been re-
ported as 3.3 and 10 days, respectively.8 As one would
expect, ICU and hospital stay are both reduced after
TEVAR.
The incidence of neurologic complications ranging
from 9% to 28% in historical OSR series also helped estab-
lish momentum for endovascular treatment options for
CTBAD.9,27-29 Contemporary series report a risk for spinal
JOURNAL OF VASCULAR SURGERY
1222 Conway et al May 2014cord injury of between 1.1% and 4.8% and for stroke of be-
tween 1.1% and 5.6%.9-11 Modern perfusion strategies,
avoidance of left subclavian artery clamping, active cooling,
the routine use of neurophysiologic monitoring, CSF
drainage, and careful hemodynamic regulation peri-
operatively are likely to account for the improvements in
neurologic outcome after surgical repair of CTBAD.
Meta-analysis data quotes an incidence of spinal cord injury
with TEVAR of 0.43% (range, 0%-2.8%) and a stroke inci-
dence of 0.82% (range, 0%-6.7%).8 The low incidence of
paraplegia is likely due to only a small portion of the aorta
being covered and, hence, fewer intercostal arteries are
compromised, as well as the lack of hemodynamic insta-
bility in the perioperative period.
We attribute the low incidence of postoperative perma-
nent hemodialysis in our cohort to the maintenance of
renal artery perfusion with cold blood during the proce-
dure. Others have noted an incidence of 0.9% to 5.9% of
patients requiring permanent hemodialysis after surgical
repair, in keeping with our results.9,10 Postoperative renal
failure occurred in 4.8% and 21% of patients in the work
by Zoli et al9 and Pujura et al,10 respectively. In other
studies, renal failure occurred in 2.6% (range, 1.4%-5.9%)
of patients after TEVAR for CTBAD.8,30,31
An adverse outcome was noted in 26% of patients in
the work by Zoli et al,9 similar to our results. This demon-
strates that surgical repair still caries a signiﬁcant risk,
despite improvements in outcomes in recent years.
Although questions remain about the long-term
durability of TEVAR for CTBAD, the low rates of reinter-
vention in those treated with surgical repair are well
known. We noted a freedom from reintervention rate of
99%, 90%, and 86% at 1, 5, and 7 years, respectively. Zoli
et al9 reported a freedom from reoperation rate of 99%,
93%, and 83% at 1, 5, and 10 years, respectively, with a
mean time to distal aorta-related reoperation of 5.7 6
2.9 (standard deviation) years.9
Persistent FL perfusion is an independent risk factor of
progressive aortic enlargement and adverse long-term
outcome.32 It was anticipated that TEVAR would induce
aortic remodeling by sealing the entry site.33 Complete
FL thrombosis after TEVAR for chronic aortic dissection
occurs in only 40% to 80% of patients at the level of the de-
vice and in 0% to 40% of patients distal to the de-
vice.5,11,19,23,26,31 Reintervention, which is commonly
required for endoleak or dilatation of the distal aorta or
FL, has rates ranging from 0% to 60% in studies with a me-
dian follow-up of 31 months.8 Even in the presence of FL
thrombosis, the distal thoracic or abdominal aorta may
continue to enlarge.18 Although surgery reverses the natu-
ral history of the disease, the failure to obliterate the FL in a
large number of patients suggests that TEVAR for CTBAD
may not always be a deﬁnitive treatment.
Some have suggested that an aortic diameter>4 cm, FL
diameter of >22 mm, and FL patency are predictive of late
aortic enlargement.7,34 FL thrombosis and aortic remodel-
ing are only predictable in dissections limited to the
descending thoracic aorta with accessible proximal anddistal seal zones.35,36 It may therefore be appropriate to
direct TEVAR toward patients with such limited pathology
or in high-risk patients with pre-existing morbidity, such as
chronic obstructive pulmonary disease, who would beneﬁt
from less invasive surgery. As our data have shown, those pa-
tients requiring redo operations or anticipated prolonged
pump time would likely beneﬁt from an endovascular
approach. Prolonged pump time is anticipated in patients
with more complicated anatomy where the aneurysm ex-
tends to the left subclavian artery, such that proximal clamp-
ing is not possible. In such cases, DHCA is used. The need
for this could be avoided by an endovascular approach with
extra-anatomic bypass. Alternatively, OSR could be used for
younger patients with less comorbidity where a durable
long-term outcome in the setting of acceptable morbidity
and mortality would be seen as preferential.
Our study is limited by the factors inherent to a retro-
spective review. The results are also limited because they
reﬂect the work of a single surgeon. The surgeon’s selec-
tion bias cannot be accounted for by a retrospective study.
Patient selection bias may have partially led to the
improved outcomes seen compared with historical data
sets, because those who were believed to be too sick for
traditional OSR in the current endovascular era may have
been referred for TEVAR. It is difﬁcult to ascertain how
many patients who were turned down for OSR during
the study period because they were deemed to be too
high risk subsequently underwent TEVAR, and what the
endovascular outcomes were in this group of patients.
Our population was a median age of 57.0 years, which
may have also added bias to our results because the rela-
tively young age of this cohort may have led to improved
outcomes. Any comparisons between our data and other
contemporary series, as well as endovascular publications
should be made with caution in the absence of matched pa-
tient population baseline characteristics. Our study also
included hemodynamically stable patients with contained
ruptures. The role of OSR or TEVAR for unstable patients
has not been addressed by these data.
CONCLUSIONS
Early outcomes after OSR of CTBAD have improved
in recent years in high-volume aortic centers. This is now
evident in several contemporary series. Long-term out-
comes in those patients who survive conﬁrm that OSR
reverses the natural history of CTBAD and provides a du-
rable outcome. TEVAR may not be a deﬁnitive treatment
because persistent FL ﬂow predisposes to ongoing aortic
dilatation, despite improvements in early morbidity. Pa-
tients requiring redo operations or anticipated prolonged
pump time need further evaluation to determine whether
conventional OSR or TEVAR, if feasible, is the optimal
treatment option.
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